What Happened
The public comment period on a significant FDA proposal closed on July 30, 2026. The proposal, issued on April 30, 2026, would permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. After an extension, the comment window ended, and a final ruling is now pending. The closing of the comment period marks the point at which the debate over the proposal gives way to the agency's decision-making.
What the 503B Bulks List Is
The 503B Bulks List is the list of active ingredients that large outsourcing facilities, known as 503B compounders, are legally allowed to use in their preparations. These facilities operate under a specific regulatory framework that permits larger-scale compounding than traditional pharmacies, but only within defined boundaries. The Bulks List is one of those boundaries: if an ingredient is not on it, 503B facilities generally cannot compound with it in bulk. Placement on or exclusion from that list is therefore a powerful lever, because it effectively determines whether large-scale compounding of a given active ingredient can continue at all.
The Substance of the Proposal
The FDA's April 30 proposal would permanently exclude three GLP-1 active ingredients, semaglutide, tirzepatide, and liraglutide, from the list. If finalized, the exclusion would curtail large-scale compounding of these GLP-1s by removing the legal basis for 503B facilities to use them in bulk. The word permanent is significant. It distinguishes this from temporary measures tied to drug-shortage conditions, which come and go as supply changes. A permanent exclusion would set a lasting rule rather than a situational one.
Why the Timing Matters
The comment period was extended before closing on July 30, 2026, reflecting the level of interest the proposal drew. Compounding stakeholders, manufacturers, and patient advocates all had reason to weigh in, given how much the outcome could reshape the supply landscape for these compounds. With the window now shut, the decision moves to the FDA, and a final ruling is pending. The extension itself is a signal of how contested and consequential the proposal is regarded to be.
This proposal sits alongside the year's other compounding-related developments, including enforcement actions over marketing claims. Together they trace a tightening regulatory posture toward compounded GLP-1s across multiple fronts. The Bulks List proposal is arguably the more structural of these, because it addresses the legal foundation for bulk compounding rather than individual marketing conduct. Where warning letters target what companies say, the Bulks List governs what large facilities can legally make.
What It Means
For anyone tracking the compounding landscape, the closed comment period marks a transition from debate to decision. If the exclusion is finalized, it would reshape how, and whether, large outsourcing facilities can produce these GLP-1s at scale. The outcome will be a defining factor in the compounding side of the GLP-1 story, and it will help set the rules under which the compounded market operates going forward.
Important Note
This article is for educational and research reference purposes only. It does not provide dosing advice for human use. Peptide compounds discussed here are sold for research purposes, and nothing here constitutes medical advice. Approved medications should only be used under physician supervision.